3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
48
Prostatic Neoplasms, Castration-Resistant
3
Adenocarcinoma
3
Urogenital Neoplasms
2
Salivary Gland Neoplasms
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Neoplasm Metastasis
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Biochemically Recurrent Prostate Cancer
2
Urogenital Diseases
1
Triple Negative Breast Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
fludarabine
52
Cyclophosphamide
50
venetoclax
47
Azacitidine
44
fludarabine phosphate
41
Whole-Body Irradiation
33
Specimen Handling
31
Mycophenolic Acid
30
Tacrolimus
28
Melphalan
28
Busulfan
27
Cytarabine
25
Stem Cell Transplantation
23
Decitabine
23
Biopsy
22
Granulocyte Colony-Stimulating Factor
19
Sirolimus
16
Peripheral Blood Stem Cell Transplantation
16
Filgrastim
16
Thiotepa
15
decitabine and cedazuridine drug combination
14
Injections
13
Cyclosporine
13
ruxolitinib
9
Methotrexate
9
Mesna
9
Hematopoietic Stem Cell Transplantation
9
X-Rays
8
Idarubicin
8
Daunorubicin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
darolutamide
×
1 year
×
Clear all
No trials found.